Physician profile
Ann Ellison
NPI 1821378282
$829.20
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.28 · 2022: $50.50 · 2023: $262 · 2024: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.67 | 2022-2024 | |
| Novo Nordisk INC | $182.65 | 2023-2024 | Wegovy |
| Shield Therapeutics INC | $88.41 | 2024 | |
| Ibsa Pharma INC. | $78.07 | 2023-2024 | Tirosint, Licart, Tirosint |
| Lilly USA, LLC | $44.16 | 2022-2024 | Reyvow, Emgality, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.74 | 2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $20.65 | 2022 | |
| Glaxosmithkline, LLC. | $18.92 | 2021 | |
| Antares Pharma, INC. | $18.40 | 2024 | Xyosted |
| Astellas Pharma US INC | $17.71 | 2024 | Veozah |
| Organon LLC | $16.17 | 2024 | |
| Merck Sharp & Dohme LLC | $14.36 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.29 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.